Compare iShares MSCI Canada (TSX) (EWC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs TG Therapeutics Inc — how do they compare? iShares MSCI Canada (TSX) trades at $59.37, while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWC | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $59.06 |
52-Week Low | $45.86 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.32, up 0.24% today, with a bullish technical signal driven by moving averages but caution from overbought RSI levels. The stock shows strong support at $59 and resistance at $60. Recent corporate actions include a dividend scheduled for June 2026, while financial ratios are unavailable in the current data.
The outlook for EWC is mixed, with technical strength offset by overbought conditions. Investment opportunities hinge on sustained bullish momentum above $60, but risks include potential pullbacks from current highs and reliance on broader market trends given limited fundamental data.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
